Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5273482
Max Phase: Preclinical
Molecular Formula: C54H64F4N8O6S2
Molecular Weight: 1061.28
Associated Items:
ID: ALA5273482
Max Phase: Preclinical
Molecular Formula: C54H64F4N8O6S2
Molecular Weight: 1061.28
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCCCCCNC(=O)c2ccc(N3C(=S)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)C3(C)C)cc2F)C(C)(C)C)cc1
Standard InChI: InChI=1S/C54H64F4N8O6S2/c1-33-45(74-32-62-33)35-19-17-34(18-20-35)30-61-48(70)43-28-39(67)31-64(43)49(71)46(52(2,3)4)63-44(68)16-14-12-10-8-7-9-11-13-15-25-60-47(69)40-24-23-38(27-42(40)55)66-51(73)65(50(72)53(66,5)6)37-22-21-36(29-59)41(26-37)54(56,57)58/h17-24,26-27,32,39,43,46,67H,7-16,25,28,30-31H2,1-6H3,(H,60,69)(H,61,70)(H,63,68)/t39-,43+,46-/m1/s1
Standard InChI Key: YLEYRJVYSVNVMW-ILGHAVELSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1061.28 | Molecular Weight (Monoisotopic): 1060.4326 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S.. (2019) Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer., 62 (2): [PMID:30629437] [10.1021/acs.jmedchem.8b01631] |
Source(1):